Press release:


IRVINE, CA, July 10, 2015 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in
the science of heart valves and hemodynamic monitoring, today announced that it has agreed to
acquire CardiAQ Valve Technologies, Inc., a privately held company and developer of a
transcatheter mitral valve replacement system.

“Edwards’ primary strategy is to create valuable therapies that transform patient care. We
believe the acquisition and integration of CardiAQ will advance our development of a
transformational therapy for patients with mitral valve disease who aren’t well-served today,” said
Michael A. Mussallem, Edwards’ chairman and CEO. “While still early in the development of this
therapy, the progress of the team of employees and clinicians working on our FORTIS mitral
replacement system has reinforced our confidence in a catheter-based approach. We believe the
experiences and technologies of FORTIS and CardiAQ are complementary and that this
combination will enable important advancements for patients.”

CardiAQ has received a U.S. Food and Drug Administration (FDA) Investigational Device
Exemption (IDE) approval to conduct an early feasibility study of up to 20 patients, and also plans to
initiate a CE Mark study in Europe.

“CardiAQ is proud of our pioneering efforts in the early development of this transcatheter
mitral valve therapy conceived by cardiac surgeon Arshad Quadri, M.D. We believe our technology,
which incorporates multiple delivery approaches with a single valve, shows great promise for
patients,” said Rob Michiels, chief executive officer of CardiAQ.

“We look forward to joining Edwards, whose experience and leadership as a developer of
breakthrough therapies for heart valve disease will advance our work,” said J. Brent Ratz, cofounder,
president and chief operating officer of CardiAQ.

The purchase price is up to $400 million, including $350 million in cash at closing, and the
remainder payable upon achievement of a European regulatory milestone. The transaction remains
subject to customary closing conditions. Edwards expects that this acquisition will be slightly
dilutive to 2015 earnings per share. The company will provide updated financial guidance for 2015
when second quarter earnings are released on July 28.

As an update to the temporary pause in the FORTIS program, working closely with its global
clinical investigators, Edwards recently completed its review and has reached agreement on
protocol revisions to re-start enrollment.
The CardiAQ and FORTIS valve systems are not approved for sale in any country.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic
monitoring. Driven by a passion to help patients, the company partners with clinicians to develop
innovative technologies in the areas of structural heart disease and critical care monitoring,
enabling them to save and enhance lives. Additional company information can be found at


About CardiAQ Valve Technologies

Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary transcatheter
mitral valve (TMV) implant that can be delivered through multiple delivery systems. Through its
unique anchoring mechanism that engages and utilizes the patient’s native mitral valve anatomy,
physicians will be able to implant a new mitral valve within a beating heart without circulatory
support, thus avoiding open-heart surgery. Orbimed led the series B financing and is CardiAQ’s
largest shareholder. Other venture investors include Broadview, Advent and Versant.

This news release includes forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forwardlooking
statements include, but are not limited to, statements by Michael Mussallem, Rob Michiels
and J. Brent Ratz regarding the timing and status of the transaction, and the timing, impact and
success of clinical development of mitral valve replacement technologies. Forward-looking
statements are based on estimates and assumptions made by management of the company and
are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our
forward-looking statements speak only as of the date on which they are made and we do not
undertake any obligation to update any forward-looking statement to reflect events or
circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by the forward-looking statements based on a number of
factors including but not limited to unexpected impediments or delays in closing the transaction,
unexpected outcomes after more expanded clinical experience with the devices, unexpected
changes or delays related to product supply, potentials for unexpected regulatory or quality
developments, competitive dynamics, global economic conditions and customer acceptance.
These factors are detailed in the company's filings with the Securities and Exchange Commission
including its Annual Report on Form 10-K for the year ended December 31, 2014.

Edwards, Edwards Lifesciences, the stylized E logo and Edwards FORTIS are trademarks of
Edwards Lifesciences Corporation. All other trademarks are the property of their respective

Media Contact: Sarah Huoh, 949-250-5070
Investor Contact: David K. Erickson, 949-250-6826